Company
Thetis Pharmaceuticals
Thetis is a clinical-stage pharmaceutical company developing first-in-class, oral TP-317 for inflammatory bowel disease (IBD) and solid tumors.
Also known as Thetis Pharmaceuticals LLC
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- Essex, Connecticut, United States
- Legal name
- Thetis Pharmaceuticals LLC
Claim, correct or request removal
Record updated 23 October 2026
About
TP-317 is a Resolvin E1 (RvE1) drug that activates BLT1 — a GPCR expressed on epithelial and immune cells — to restore and maintain tissue and immune homeostasis.
Funding snapshot
- Total raised
- $14.6MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Undisclosed, $560K2026-08-13
Funding rounds
- Round, 2026
- $560K2026-08-13, SEC form D sold
- Grant
- $9M2025-01-09, Company stated
- Grant
- $2.3M2024-08-28, Company stated
- Grant
- $3M2023-03-15, Company stated
- Round, 2022
- $1.1M2022-06-27, SEC form D sold, 9 investors
- Round, 2018
- $796K2018-08-06, SEC form D sold, 8 investors
- Round, 2016
- $4.1M2016-06-17, SEC form D sold, 52 investors
- Round, 2016
- $1.4M2016-01-29, SEC form D sold, 16 investors
- Round, 2012
- $5.7M2012-12-03, SEC form D sold, 32 investors
- Round, 2011
- $1.5M2011-08-11, SEC form D sold, 14 investors
Products
- Other
- TP-317
Loading relationship preview